Could treatment of iron deficiency both improve ADHD and reduce cardiovascular risk during treatment with ADHD drugs?
Could treatment of iron deficiency both improve ADHD and reduce cardiovascular risk during treatment with ADHD drugs?
Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most common childhood-onset neuropsychiatric conditions. Despite extensive research, the etiopathophysiological factors underlying ADHD are not completely understood. It has been suggested that iron deficiency may contribute to ADHD symptoms severity. Whereas evidence from studies based on serum ferritin measures, a marker of peripheral iron status, is somewhat mixed, preliminary recent evidence suggests a deficiency of brain iron in individuals with ADHD. Therefore, it has been proposed that either a deficiency of peripheral iron or a dysfunction of the blood–brain barrier, in the presence of normal peripheral iron levels, may contribute to low brain iron levels, which, in turn, would increase the risk for ADHD symptoms in a subgroup of individuals with this disorder. It has also been found that individuals with ADHD may be at increased risk of severe cardiovascular events during treatment with ADHD drugs, although the extent to which this occurs in ADHD patients compared to non-ADHD individuals is still matter of investigation. Since iron depletion has been recently reported as a risk factor for adverse prognosis in heart failure, iron deficiency might contribute both to ADHD symptoms severity before treatment and to increased risk of severe cardiovascular events during treatment with ADHD drugs in a selected subgroup of patients. Therefore, we hypothesize that the effective treatment of iron deficiency might lead both to improvement of ADHD symptoms severity and to a decrease of the risk of cardiovascular events during treatment with ADHD drugs. If empirical studies confirm this hypothesis, the clinician would be advised to systematically check iron status and effectively treat iron deficiency before starting a pharmacological treatment with ADHD drugs.
246-249
Parisi, Pasquale
a9ee1126-02e0-41d0-a97a-66d77e8b1173
Villa, Maria Pia
ad451625-bbd1-4922-a841-e03ceb28e560
Donfrancesco, Renato
53d1b491-be76-4f91-8a67-99d1d910c7da
Miano, Silvia
d76e56bc-ffca-45ec-b2b7-d81a878df02a
Paolino, Maria Chiara
81a97291-d8db-4864-bfcb-05844e7d6d44
Cortese, Samuele
53d4bf2c-4e0e-4c77-9385-218350560fdb
August 2012
Parisi, Pasquale
a9ee1126-02e0-41d0-a97a-66d77e8b1173
Villa, Maria Pia
ad451625-bbd1-4922-a841-e03ceb28e560
Donfrancesco, Renato
53d1b491-be76-4f91-8a67-99d1d910c7da
Miano, Silvia
d76e56bc-ffca-45ec-b2b7-d81a878df02a
Paolino, Maria Chiara
81a97291-d8db-4864-bfcb-05844e7d6d44
Cortese, Samuele
53d4bf2c-4e0e-4c77-9385-218350560fdb
Parisi, Pasquale, Villa, Maria Pia, Donfrancesco, Renato, Miano, Silvia, Paolino, Maria Chiara and Cortese, Samuele
(2012)
Could treatment of iron deficiency both improve ADHD and reduce cardiovascular risk during treatment with ADHD drugs?
Medical Hypotheses, 79 (2), .
(doi:10.1016/j.mehy.2012.04.049).
Abstract
Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most common childhood-onset neuropsychiatric conditions. Despite extensive research, the etiopathophysiological factors underlying ADHD are not completely understood. It has been suggested that iron deficiency may contribute to ADHD symptoms severity. Whereas evidence from studies based on serum ferritin measures, a marker of peripheral iron status, is somewhat mixed, preliminary recent evidence suggests a deficiency of brain iron in individuals with ADHD. Therefore, it has been proposed that either a deficiency of peripheral iron or a dysfunction of the blood–brain barrier, in the presence of normal peripheral iron levels, may contribute to low brain iron levels, which, in turn, would increase the risk for ADHD symptoms in a subgroup of individuals with this disorder. It has also been found that individuals with ADHD may be at increased risk of severe cardiovascular events during treatment with ADHD drugs, although the extent to which this occurs in ADHD patients compared to non-ADHD individuals is still matter of investigation. Since iron depletion has been recently reported as a risk factor for adverse prognosis in heart failure, iron deficiency might contribute both to ADHD symptoms severity before treatment and to increased risk of severe cardiovascular events during treatment with ADHD drugs in a selected subgroup of patients. Therefore, we hypothesize that the effective treatment of iron deficiency might lead both to improvement of ADHD symptoms severity and to a decrease of the risk of cardiovascular events during treatment with ADHD drugs. If empirical studies confirm this hypothesis, the clinician would be advised to systematically check iron status and effectively treat iron deficiency before starting a pharmacological treatment with ADHD drugs.
This record has no associated files available for download.
More information
Accepted/In Press date: 16 April 2012
e-pub ahead of print date: 25 May 2012
Published date: August 2012
Organisations:
Clinical Neuroscience
Identifiers
Local EPrints ID: 380403
URI: http://eprints.soton.ac.uk/id/eprint/380403
ISSN: 0306-9877
PURE UUID: 67768b0c-1811-4c27-bce2-6f4ca7a726fb
Catalogue record
Date deposited: 21 Aug 2015 16:18
Last modified: 15 Mar 2024 03:52
Export record
Altmetrics
Contributors
Author:
Pasquale Parisi
Author:
Maria Pia Villa
Author:
Renato Donfrancesco
Author:
Silvia Miano
Author:
Maria Chiara Paolino
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics